A Controlled Challenge Study on Di(2-ethylhexyl) Phthalate (DEHP) in House Dust and the Immune Response in Human Nasal Mucosa of Allergic Subjects

Tom Deutschle,1 Rudolf Reiter,1 Werner Butte,2 Birger Heinzow,3 Tilman Keck,1 and Herbert Riechelmann4

1Department of Otorhinolaryngology, University of Ulm, Medical School, Ulm, Germany; 2Institute for Pure and Applied Chemistry, University of Oldenburg, Oldenburg, Germany; 3State Agency for Nature and Environment of Schleswig-Holstein, Department of Environmental Health and Toxicology, Flintbek, Germany; 4Department of Otorhinolaryngology, University Hospital, Medical University, Innsbruck, Austria

Background: Few studies have yet addressed the effects of di(2-ethylhexyl) phthalate (DEHP) in house dust on human nasal mucosa.

Objectives: We investigated the effects of house dust containing DEHP on nasal mucosa of healthy and house dust mite (HDM)—allergic subjects in a short-term exposure setting.

Methods: We challenged 16 healthy and 16 HDM-allergic subjects for 3 hr with house dust at a concentration of 300 µg/m³ containing either low (0.41 mg/g) or high (2.09 mg/g) levels of DEHP. Exposure to filtered air served as control. After exposure, we measured proteins and performed a DNA microarray analysis.

Results: Nasal exposure to house dust with low or high DEHP had no effect on symptom scores. Healthy subjects had almost no response to inhaled dust, but HDM-allergic subjects showed varied responses: DEHPlow house dust increased eosinophil cationic protein, granulocyte-colony–stimulating factor (G-CSF), interleukin (IL)-5, and IL-6, whereas DEHPhigh house dust decreased G-CSF and IL-6. Furthermore, in healthy subjects, DEHP concentration resulted in 10 differentially expressed genes, whereas 16 genes were differentially expressed in HDM-allergic subjects, among them anti–Müllerian hormone, which was significantly up-regulated after exposure to DEHPhigh house dust compared with exposure to DEHPlow house dust, and fibroblast growth factor 9, IL-6, and transforming growth factor–β1, which were down-regulated.

Conclusions: Short-term exposure to house dust with high concentrations of DEHP has attenuating effects on human nasal immune response in HDM-allergic subjects, concerning both gene expression and cytokines.

Key Words: allergy, cytokines, DEHP, di(2-ethylhexyl) phthalate, house dust, hypersensitivity, microarray analysis, nasal challenge, nasal exposure system, nasal mucosa.

Materials and Methods

Subjects and eligibility. Sixteen healthy and 16 house dust mite (HDM)—allergic human subjects participated in this study exposure. Twenty subjects were male, and 12 were female, with ages ranging from 22 to 32 (mean, 24) years. Subjects without clinically relevant nasal disorders, except for allergic subjects suffering from HDM allergy, were eligible, as confirmed by rhinologic history and nasal endoscopy. We identified HDM-allergic subjects by skin prick test according to the guidelines of the European Academy of Allergy and Clinical Immunology (Dreborg and Frew 1993): a CAP [or RAST (radioallergosorbent test)] class of at least 3 (Phadia AB, Uppsala, Sweden) and a positive nasal or conjunctival provocation test (Riechelmann et al. 2003b). Exclusion criteria were smoking, pregnancy, or lactation, allergy to allergens other than HDM, a clinically relevant nasal septal deviation or turbinate hypertrophy, rhinitis medicamentosa, chronic rhinosinusitis, acute rhinosinusitis within the preceding 6 weeks, previous sinus surgery, bronchial hyperreactivity, lung emphysema, and any systemic therapy with corticosteroids.
or anti-inflammatory drugs or nasal corticosteroid therapy within the preceding 6 weeks. Our study was approved by the ethics committee of the University of Ulm, and each participant gave written informed consent.

Study design. We randomly assigned subjects to four groups exposed to house dust with either low or high concentrations of DEHP (Figure 1): We challenged eight healthy and eight allergic subjects with DEHPlow (0.41 mg/g) house dust, and eight healthy and eight allergic subjects with DEHPhigh (2.09 mg/g) house dust. We challenged each subject twice in a nose-only exposure setting: once with the house dust in a concentration of 300 µg/m³ for 3 hr, and once with filtered air (control, 0 µg/m³) for the same time period. The sequences of exposures varied in a random order and were single blinded. We kept a time interval of at least 14 days between the two exposures. We completed visual analogue scales (VASs) immediately before and after exposure. We collected nasal fluid on one nasal side 3 hr after the first exposure, and took a nasal biopsy on the opposite side. After the second exposure, we switched both sides.

Aerosol exposure. We generated aerosols with a modified rotation plate aerosol generator (Small Scale Powder Disperser, model 3433; TSI GmbH, Aachen, Germany) (Riechelmann et al. 2007). We dispersed the dust in conditioned air (35% relative humidity, 21°C). During the exposures, we constantly recorded the concentration of DEHP and other phthalates by gas chromatography/mass spectrometry (HP G1800A, GCD series II MS; Agilent Technologies, Santa Clara, California, USA) (Butte et al. 2001).

We determined concentrations of several indoor allergens, including Der p1, Der f1, and Fel d1, with the Dustscreen immunodot assay (CMG Heska, Fribourg, Switzerland). We detected the presence of grass, alder, birch, and yew pollen by light microscopy. Measurements of polycyclic aromatic hydrocarbons, polychlorinated biphenyls, biocides, phenoxyacetic acids, heavy metals, tansides, and other contaminants are described elsewhere (Riechelmann et al. 2003a). We dispersed the dust in conditioned air (35% relative humidity, 21°C). During the exposures, we constantly recorded the accuracy of dust exposures employing a laser particle counter (Microair-5230; Hiac Royco, Leonberg, Germany).

House dust. We collected the house dust in 42 households using commercial vacuum cleaners. We sieved the content of the vacuum cleaner bags to a fraction of less than 32 µm and then pooled and divided the dust in two fractions. We used one fraction directly for exposure (DEHPlow), and enriched the second fraction with DEHPhigh in a rotary evaporator (Rotavapor R-200; Buchi, Flawil, Switzerland). Thus, the two house dust fractions were identical except for their content of DEHP. We measured the concentrations of DEHP and other phthalates by gas chromatography/mass spectrometry (HP G1800A, GCD series II MS; Agilent Technologies, Santa Clara, California, USA) (Butte et al. 2001).

Figure 1. Study flow chart. Healthy and HDM-allergic subjects were randomly arranged for challenge with either DEHPlow or DEHPhigh house dust and the sequence of dust (300 µg/m³) and control (filtered air, 0 µg/m³) exposure.

We diluted nasal secretions 1:10 and analyzed cytokine concentrations on a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Munich, Germany) for IL-2, IL-4, IL-5, IL-6, IL-8, interferon-γ (IFNγ), and granulocyte-colony-stimulating factor (G-CSF) employing a multiplex cytokine assay for seven cytokines (Bio-Rad Laboratories) with the Bio-Plex Manager Software 3.0 (Bio-Rad Laboratories). We measured eosinophil cationic protein (ECP) using a fluorescence enzyme immunoassay with the UniCAP 100 Diagnostic System (Phadia, Freiburg, Germany). We performed all assays according to the manufacturers’ recommendations.

DNA microarray analysis. We performed intraindividual differential (control vs. house dust exposure) gene expression analysis from four subjects of each exposure group. We randomly selected subjects for microarray analysis. The cDNA microarray consisted of 1,232 human genes, 10 different extrahuman spiking controls from Arabidopsis and Sinorhizobium genes, and randomized negative controls (i.e., oligonucleotides that do not bind human mRNA) in 300 and in 12 spot quadruples as described previously (Riechelmann et al. 2007). Briefly, we spotted oligomers (Operon Biotechnologies, Cologne, Germany) on Ultra Gaps 2 coated slides (Corning, Schiphol-Rijk, The Netherlands). We isolated total RNA from biopsy specimens using the RNeasy Mini Kit (Qiagen, Cologne, Germany). For spiking controls, we synthesized synthetic mRNA of 10 different Arabidopsis and Sinorhizobium genes on an ABI 394 synthesizer (Purimex, Staufenberg, Germany). We added 0.2–10 pg of this spiking mRNA to the total RNA of control and exposure specimens, resulting in ratios of 1:2 to 1:10. We reverse transcribed mRNA, labeled it using Superscript-2 (Invitrogen, Karlsruhe, Germany) in combination with the 3 DNA Array Kit 350 (Genisphere, Hatfield, PA, USA), and hybridized it with the spotted oligonucleotides at 57°C overnight. We measured the distance from the left border of the scale to the marks made by the subjects in millimeters and calculated the difference after versus before exposure. Positive values indicate a degradation of the appropriate symptom after challenge compared with the control.

Nasal secretions and biopsy. At 3 hr post-exposure, an open-cell flexible polyurethane foam sampler of 28 × 18 × 6 mm was placed into one nasal cavity posterior to the mucocutaneous junction under direct visualization and left in place for 10 min. After removal, we extracted the secreted fluid from the sampler by centrifugation and stored it at −20°C (Riechelmann et al. 2003a). On the opposite side, we took a nasal inferior turbinate biopsy under local anesthesia with a Fokkens forceps (Explorent, Tuttlingen, Germany).

Cytokines and eosinophil cationic protein. We diluted nasal secretions 1:10 and analyzed cytokine concentrations on a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Munich, Germany) for IL-2, IL-4, IL-5, IL-6, IL-8, interferon-γ (IFNγ), and granulocyte-colony-stimulating factor (G-CSF) employing a multiplex cytokine assay for seven cytokines (Bio-Rad Laboratories) with the Bio-Plex Manager Software 3.0 (Bio-Rad Laboratories). We measured eosinophil cationic protein (ECP) using a fluorescence enzyme immunoassay with the UniCAP 100 Diagnostic System (Phadia, Freiburg, Germany). We performed all assays according to the manufacturers’ recommendations.
scanned microarrays with a dual-laser microarray scanner (GenePix 4000 B; Axon Instruments, Foster City, CA, USA) recorded with GenePix Pro 4.1 software (Axon Instruments) and carried out further analysis using the platform-independent java application ArrayNorm, version 1.7.2 (Piel et al. 2004). After background subtraction and Lowess subgrid normalization, we performed replicate handling as we averaged quadrupled spots within a slide. Accordingly, we calculated the log₂-transformed cyanine 5:cyanine 3 ratio (log₂-expression ratio) for all genes and controls. We identified differentially expressed genes between DEHPlow and DEHPhigh exposure using Student’s t-test with Bonferroni step-down correction to adjust the critical alpha limit of 0.05. We considered only genes with valid expression values in each biologic replicate for analysis. We annotated genes according to the glossary of the Human Genome Organisation (HUGO) (Wain et al. 2004). The full list of array data is available on the server of the Ear, Nose, and Throat Department Ulm (2008).

**Results**

**House dust.** The concentration of DEHP in the DEHPlow house dust fraction was 0.41 mg/g. Enrichment of house dust with DEHP yielded to a 5-fold higher concentration of 2.09 mg/g in the DEHPhigh fraction. Table 1 lists the amounts of phthalates, major allergens, fungal spores, and endotoxin activity. Pollen from weeds, alder, birch, and yew were identified but not quantified. and ECP in nasal secretions in healthy subjects. Nasal challenge of eight HDM-allergic subjects with DEHPlow house dust resulted in significantly elevated median concentrations of ECP (p = 0.01), G-CSF (p = 0.02), IL-5 (p = 0.03), and IL-6 (p = 0.02) in nasal secretions compared with the appropriate control exposure with filtered air (Figure 2). The eight HDM-allergic subjects that we challenged with DEHPhigh house dust showed significantly

**Symptom scores.** Nasal exposure to DEHPlow or DEHPhigh house dust did not cause significant changes in nasal symptom scores concerning dryness, itching and sneezing, mucous membrane burning, and unpleasant smell compared with filtered air exposure (Table 2). HDM-allergic subjects complained about nasal obstruction and hypersecretion (Table 2). HDM-allergic subjects (n = 16) after exposure to DEHPlow house dust, but this effect was not significant (p > 0.05).

**Cytokines and ECP.** Sampling of epithelial lining fluid with a polyurethane foam sampler from all subjects yielded to a median volume of 275 µL (IQR, 180–450 µL). Table 3 outlines the results of protein determination.

Independent from exposure to DEHPlow or DEHPhigh house dust, we found no significant changes in the concentrations of cytokines and ECP in nasal secretions in healthy subjects. Nasal challenge of eight HDM-allergic subjects with DEHPlow house dust resulted in significantly elevated median concentrations of ECP (p = 0.01), G-CSF (p = 0.02), IL-5 (p = 0.03), and IL-6 (p = 0.02) in nasal secretions compared with the appropriate control exposure with filtered air (Figure 2). The eight HDM-allergic subjects that we challenged with DEHPhigh house dust showed significantly

| Table 1. Phthalates, major allergens, fungal spores, and endotoxin activity in house dust. |
| --- |
| Compound or allergen | Mean ± SD |
| Phthalic acid esters (phthalates) (mg/kg) | n-Butyl benzyl phthalate (BBP) |
| | 34.0 ± 4.05 |
| Diisobutyl phthalate (DiBP) | 31.7 ± 3.36 |
| Di-n-butyl phthalate (DnBP) | 49.2 ± 5.7 |
| Diethyl phthalate (DEP) | 44.5 ± 4.17 |
| Dimethyl phthalate (DMP) | 3.1 ± 0.25 |
| Di-n-octyl phthalate (DnOP) | 4.23 ± 0.44 |
| Major allergens (μg/g) | Der p1 |
| | 2.0 ± 0.1 |
| Der f1 | 2.0 ± 0.1 |
| Fel d1 | 5.4 ± 0.5 |
| Fungal spores (cfu/g) | Penicillium spp. |
| | 72,000 ± 6,200 |
| Aspergillus spp. | 6,000 ± 720 |
| Endotoxin activity (EU/g) | 15.8 ± 0.6 |

**Table 2. Symptom scores (10-cm-long horizontal VAS) after nasal challenge with house dust: difference [median (IQR)] after compared with before exposure.**

| Symptom | Control | Exposure | Control | Exposure |
| --- | --- | --- | --- | --- |
| Healthy subjects (n = 16) | | | | |
| OBs | -0.5 (0.05–0.85) | 0.1 (0.3–0.9) | -0.65 (–1.25–2.95) | -0.6 (–0.95–2.5) |
| HS | -0.65 (–1.45–0.05) | -0.9 (–1.7–0) | -0.95 (–2.35–0.55) | -0.11 (–1.7–0.05) |
| IS | 0 (0–0.35) | -0.05 (–0.4–0) | 0.05 (–1.85–0.05) | 0 (–0.05–0.35) |
| DRY | 0.05 (–0.1–0.2) | 0.45 (0.2–2.35) | 1.3 (0.25–4) | 1.5 (0.3–3.2) |
| SME | 0.1 (0.05–0.2) | 0.1 (0.05–1.45) | 0.05 (–0.05–0.25) | 0.1 (–0.05–0.25) |
| BUR | 0 (0–0.15) | 0.2 (0–1.1) | 0.01 (–0.1–0.6) | 0 (–0.1–0.5) |

**Table 3. Concentrations of proteins in the epithelial lining fluid of 16 healthy and 16 HDM-allergic subjects after nasal challenge with house dust [median (IQR), rounded to whole numbers].**

| Protein | Control | Exposure | Control | Exposure |
| --- | --- | --- | --- | --- |
| Healthy subjects (n = 16) | | | | |
| G-CSF | 1,351 (1,049–1,690) | 817 (465–2,765) | 1,900 (1,129–3,198) | 1,656 (319–2,116) |
| IFNγ | 130 (78–180) | 147 (119–188) | 129 (84–209) | 152 (105–230) |
| IL-2 | 34 (13–48) | 34 (19–59) | 19 (4–41) | 33 (14–63) |
| IL-4 | 118 (86–136) | 126 (91–145) | 115 (84–162) | 129 (79–245) |
| IL-5 | 4 (3–41) | 5 (2–7) | 4 (3–26) | 7 (4–15) |
| IL-6 | 744 (455–1,201) | 572 (289–1,005) | 707 (481–1,048) | 506 (426–660) |
| IL-8 | 1,838 (1,300–2,507) | 1,882 (811–2,612) | 2,172 (1,65–2,802) | 1,402 (1,208–2,114) |
| ECP (ng/mL) | 57 (32–96) | 54 (10–150) | 56 (10–203) | 95 (21–242) |

Abbreviations: BUR, mucous membrane burning; HS, hypersecretion; IS, itching and sneezing; DRY, dryness; OBS, sensation of nasal obstruction; SME, unpleasant smell.

Values are pg/mL, except where indicated.
lower concentrations of G-CSF and IL-6 in nasal secretions than did the HDM-eight allergic subjects we challenged with DEHP<sub>low</sub> house dust (G-CSF, \( p = 0.04 \); IL-6, \( p = 0.001 \)) (Figure 3). We found no significant changes for the other cytokines or for ECP.

**DNA microarray gene expression analysis.**

After control and dust exposures, we obtained nasal mucosa biopsies using the Fokkens forceps from all participants. The median amount of extracted total RNA from biopsy material was 10.1 µg (IQR, 7.8–13.2 µg). We performed gene expression analysis from four subjects of each exposure group. Because of insufficient hybridization quality, we excluded two microarrays from HDM-allergic subjects from further evaluation.

In healthy subjects, we found 10 genes (0.8% of 1,232 genes) to be differentially expressed between the two exposure groups (Table 4). Chemokine (C-C motif) ligand 19 [CCL19; UniGene ID NM_006274 (UniGene, http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene)], a chemokine also known as macrophage inflammatory protein-3β (MIP-3β), showed higher expression in healthy subjects after nasal challenge with DEHP<sub>high</sub> house dust compared with exposure to DEHP<sub>low</sub> house dust (mean log<sub>2</sub>-expression ratio difference \( = 0.648; \ p = 0.017 \)).

In HDM-allergic subjects, we found 16 genes (1.3% of 1,232 genes) to be differentially expressed between the two exposure groups (Figure 4). We identified eight genes, among them anti-Müllerian hormone (AMH, UniGene ID NM_000479), whose expression was significantly higher after exposure to DEHP<sub>high</sub> house dust compared with exposure to DEHP<sub>low</sub> house dust (mean log<sub>2</sub>-expression ratio difference \( = 0.871; \ p = 0.019 \)).

We found eight genes whose expression was significantly lower, among them fibroblast growth factor 9 (FGF9, NM_002010; 0.975, \( p = 0.016 \)), lactate dehydrogenase A (LDHA, NM_005566; 1.237, \( p = 0.013 \)), and the cytokines IL-6 (IL6, NM_000600; 0.916, \( p = 0.009 \)) and transforming growth factor-β1 (TGFβ1, NM_000660; 0.621, \( p = 0.019 \)).

**Discussion**

In this study, we investigated the effects of house dust with low and high concentrations of DEHP on nasal mucosa of healthy and HDM-allergic human subjects in a short-term exposure setting. Corresponding parameters included a transcriptional profile of 1,232 genes and the concentrations of several cytokines and ECP in nasal secretions. We found two overall results: a) Healthy subjects were not significantly affected by the challenge with house dust, and b) HDM-allergic subjects perceived little of the challenge, and low concentrations of DEHP induced a silent inflammation in human nasal mucosa. However, high concentrations of DEHP attenuated the immune response based on protein and mRNA levels.

We collected and pooled house dust from 42 German homes to provide a reasonably representative sample. Coarse particles with diameters > 10 µm are deposited predominantly in the upper airways (Keck et al. 2000). Hence, we used the selected fraction with coarse particles < 32 µm for exposure. A dust concentration of 300 µg/m<sup>3</sup> is equal to that in interiors with human activity (Junker et al. 2000), in offices (Molhave et al. 2004), and in public transportation (Praml and Schierl 2000). Because of its ubiquity, DEHP appears in almost every house dust sample. Dust samples collected in office buildings in Austria showed DEHP concentrations ranging up to 3 mg/g (Hutter et al. 2006). The median concentration of DEHP in dust collected in children’s bedrooms in 346 homes in Sweden was 0.7 mg/g (Bornehag et al. 2004). These concentrations resemble the concentrations of 0.41 mg/g and 2.09 mg/g used in our study, which consequently agree with DEHP concentrations naturally occurring in house environments. The content of the major allergens Der p 1 and Der f 1 in house dust depends of several factors, such as geographic region, seasonal variation, climate conditions, age of the dwelling, and floor covering. In dwellings in the Netherlands, van Strien et al. (1994) found a mean Der p 1 concentration of 2.4 µg/g for floor dust from living rooms, but
in more than the half of the houses the maximum concentration exceeded 10 µg/g. However, the mean concentration of 0.09 µg/g (range, < 0.01–9.54 µg/g) Der p1 found in European homes within the European Community Respiratory Health Survey II is several times lower (Zock et al. 2006). Differences in allergen contents in dust samples may be caused by different dust collecting methods (Schram-Bijkerk et al. 2006). Our house dust was collected over at least 4 weeks in the whole dwelling with conventional vacuum cleaners, provided by the inhabitants themselves. When we used multilayered vacuum cleaner bags, we also included the fine dust fraction between the unique paper layers. It is possible that the long sampling time and dust extracted from the whole vacuum cleaner bag yielded Der p1 and Der f1 concentrations of 2.0 µg/g each, representing typical concentrations in house dust samples from common households. Endotoxin levels resembled concentrations found in a recent European study (Bouillard et al. 2006).

Study subjects’ nasal symptom severity is an important outcome measure in the assessment of dust-induced effects. Symptom scores based on VAS are being used increasingly for this purpose. Concerning healthy volunteers, no upper or lower respiratory symptoms were described after challenge with concentrated ambient air particles (2.3–311.1 µg/m³) (Ghio et al. 2000) or urban dust (150 and 500 µg/m³) (Riechelmann et al. 2004). However, upper respiratory symptoms were not associated with plastic wall materials (Jaakkola et al. 2000). As expected, house dust did not affect nasal function in our healthy subjects irrespective of the administered dust concentration. Although our HDM-allergic subjects had positive nasal or conjunctival provocation tests, nasal challenge with house dust did not result in distinct allergic symptoms. Apparently, the concentration of house dust and the affiliated allergen dose was too low to elicit nasal symptoms. Particularly in persistent allergic rhinitis, affected subjects can habituate to allergen and remain asymptomatic. Among our HDM-allergic subjects, we found a faint but nonsignificant association with increased nasal obstruction and hypersecretion for DEHP low house dust but not for DEHP high house dust. Phthalates and their metabolites have the potential to interact with the immune system. Concentration-dependent effects of some phthalates are described in animal and in vitro studies. In general, lower concentrations of phthalates have shown stimulatory and higher concentrations suppressive properties (Jepsen et al. 2004; Larsen

| Abbreviations: | CCL19, chemokine (C-C motif) ligand 19 (UniGene ID NM_006274); CDKN2B, cyclin-dependent kinase inhibitor 2B (NM_078487); CREBL1, cAMP responsive element binding protein-like 1 (NM_004381); FGBP, Fc fragment of IgG binding protein (NM_003989); GPX1, glutathione peroxidase 1 (NM_000479); RCN1, reticulocitinib B1, EF-hand calcium binding domain (NM_082098); SON, SON DNA binding protein (NM_081810); TGFBI, tumor necrosis factor (ligand) superfamily, member 1B (NM_003610); USP20, ubiquitin specific peptidase 20 (NM_006878); XCR1, chemokine (C motif) receptor 1 (NM_052255). Genes marked with (*) were up-regulated after challenge with DEHPlow house dust compared with the challenge with DEHPhigh house dust; the other genes were down-regulated. Values are log2-expression ratios, means, and differences in means; p-values are for Student’s t-test with Bonferroni stepdown correction; gene names are abbreviations of the Human Genome Organization (HUGO). |

### Table 4. Genes differentially expressed between DEHPlow and DEHPhigh house dust exposure in nasal mucosa of healthy subjects (individual subject values and group means).

| HUGO name | Log2-expression ratio for house dust challenge | Difference of means | p-Value |
|-----------|----------------------------------|--------------------|---------|
|            | DEHPlow | DEHPhigh | DEHPlow | DEHPhigh | DEHPhigh | DEHPlow | DEHPhigh | DEHPlow | DEHPhigh | DEHPlow | DEHPhigh | DEHPlow | DEHPhigh | DEHPlow | DEHPhigh | DEHPlow | DEHPhigh |
|            | 24      | 31      | 36      | 40      | 22      | 25      | 26      | 28      | 34      | Mean    | 22      | 25      | 26      | 34      | Mean    | 22      | 25      | 26      | 34      | Mean    | 22      | 25      | 26      | 34      | Mean    |
| CCL19(*)  | -0.412  | 0.182   | 0.417   | -0.040  | 0.037   | 0.705   | 0.211   | 0.812   | 0.714   | 0.611   | 0.648   | 0.017   |
| CREBL1(*) | -0.129  | -0.073  | -0.274  | -0.247  | -0.274  | 0.619   | 0.036   | 0.517   | 1.029   | 1.559   | 0.973   | 0.018   |
| RGN(*)    | 0.955   | 0.530   | 0.085   | 0.125   | 0.159   | 2.200   | 1.942   | 1.348   | 0.430   | 1.480   | 1.639   | 0.024   |
| SON(*)    | 0.077   | 0.095   | 0.116   | -0.370  | -0.031  | 1.504   | 1.106   | 1.733   | 0.929   | 1.318   | 1.349   | 0.002   |
| TNFSF9(*) | -0.269  | -0.201  | 0.372   | -1.115  | -0.303  | 0.621   | 0.575   | 0.603   | 0.266   | 0.616   | 0.919   | 0.012   |
| XCR1(*)   | -0.255  | 0.243   | -0.318  | -0.319  | -0.162  | 1.695   | 0.765   | 1.714   | 1.294   | 1.372   | 1.534   | 0.002   |
| CDKN2B    | -0.269  | 0.372   | 0.742   | 0.176   | 0.170   | -0.051  | -0.074  | -0.008  | 0.036   | -0.024  | 0.194   | 0.016   |
| FGBP      | 0.810   | 0.472   | 0.794   | -0.079  | 0.499   | -0.075  | -0.612  | -0.262  | -0.269  | -0.277  | 0.777   | 0.010   |
| GPX1      | 0.076   | 0.056   | 0.113   | 0.098   | 0.086   | 0.065   | 0.039   | -0.004  | -0.044  | 0.014   | 0.100   | 0.018   |
| USP20     | -0.085  | 0.168   | 0.481   | 0.331   | 0.224   | -0.636  | -0.150  | -0.942  | -1.592  | -0.805  | 1.029   | 0.005   |

Figure 4. Differentially expressed genes in nasal mucosa of six HDM-allergic subjects exposed to DEHPlow (white bars) or DEHPhigh (black bars) house dust. Values are mean fold difference in log2-expression ratios; p < 0.05 for all genes. Gene names are abbreviations of the Human Genome Organization (HUGO): AMH, anti-Müllerian hormone (NM_000479); CD3, CD83 molecule (NM_004233); CEACAM4, carcinoembryonic antigen-related cell adhesion molecule 4 (NM_001817); CREBBP, CREB binding protein (Rubinstein-Taybi syndrome) (NM_004380); ESRB3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (NM_001982); ESD, esterase D/formylglutathione hydrolase (NM_001984); FGF9, fibroblast growth factor 9 (glia-activating factor) (NM_002010); GNAT1, guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 1 (NM_000172); HLADPA1, major histocompatibility complex, class II, DP alpha 1 (NM_033554); IL6, IL-6 (NM_000660); ITGB5, integrin, beta 5 (NM_002213); KRT17, keratin 17 (NM_000422); LDHA, lactate dehydrogenase A (NM_005566); NTRK3, neurotrophic tyrosine kinase, receptor, type 3 (NM_002530); RORA, RAR-related orphan receptor A (NM_002943); TGFBI, transforming growth factor, beta 1 (NM_000660).
The effect of DEHP on nasal symptoms of HDM-allergic subjects may be concentration dependent.

Potential adverse effects of phthalates arise from their developmental and reproductive toxicity, particularly in males (Howdeshell et al. 2007). Phthalates act as endocrine disruptors because they alter the hormone profiles of both sexes by interfering with estrogen- or androgen-signaling mechanisms (Ma et al. 2006; Sharpe and Irvine 2004). In a human breast cancer cell line, DEHP mimicked estrogen in the inhibition of tamoxifen-induced apoptosis (Kim et al. 2004), and it acts as an anti-androgen in rats (Andrade et al. 2006). 

AMH is a member of the transforming growth factor-β (TGFβ) family that is implicated in the regression of Müllerian ducts in male fetuses and in the development and function of gonads. Currently, AMH is not suspected to play a major role in endocrine disruption (Sharpe 2006). However, in HDM-allergic subjects, transcription of AMH increased significantly after exposure to DEHP high house dust compared with DEHP low house dust. It remains unknown whether DEHP affects transcription of AMH in nasal mucosa tissue via an androgen or estrogen receptor mechanism or some other pathway. Some more interesting observations include the down-regulation of LDHA and FGF3 in HDM-allergic subjects after exposure to DEHP high house dust. Both genes are involved in sex determination. In the testes of rats, gene expression of LDHA is down-regulated after phthalate exposure in utero (Plummer et al. 2007) and FGF3 plays distinct roles in testis development and male sex determination (Colvin et al. 2001). In fact, the potential adverse effects of DEHP have not yet been elucidated in detail. However, in HDM-allergic subjects, exposure to DEHP high house dust attenuated this inflammatory response profile changed. We found increases in ECP, G-CSF, IL-5, and/or IL-6 after exposure to DEHP high house dust. After exposure to DEHP high house dust ECP, G-CSF, IL-5, and/or IL-6 were not increased. Additionally, FGF3 and particularly IL-6 decreased significantly after exposure to DEHP high house dust in house dust. It is not clear from the data in this study whether the applied range of exposure causes a linear or nonlinear attenuation because this study used a three-point design with no exposure (control), DEHP low house dust, and DEHP high house dust. This could be addressed by future studies by having several levels of exposure within a certain range.

As detailed above, a plausible molecular mechanism for the attenuating effects of DEHP is the repression of transcription factor NF-κB. Like DEHP, volatile organic compounds may attenuate the immune response (Wichmann et al. 2005). We found the same diminished release of cytokines after exposure to house dust with high concentrations of DEHP as was found for thalidomide (α-N-phthalimidoglutaramide), a sedative with related chemical structure and teratogenic properties (Rowland et al. 1998). However, thalidomide does not act directly on NF-κB (Rowland et al. 2001). These observations do not exclude a possible association between exposure to DEHP and suppressed gene expression via the NF-κB pathway, because the metabolites of DEHP, and not DEHP itself, interact with NF-κB.

The results of our gene expression analysis indicate an altering effect of DEHP on gene expression in human nasal mucosa. The changes demonstrated for IL-6 on the protein level are consistent with the results of gene expression analysis observed in HDM-allergic subjects: IL-6 was up-regulated after exposure to DEHP low house dust and down-regulated after exposure to DEHP high (Figure 4). We did not detect transforming growth factor-β1 (TGF-β1) protein, but transcription of TGFβ1 decreased significantly after exposure of HDM-allergic subjects to DEHP high house dust. TGF-β1 is an anti-inflammatory cytokine with comparatively high concentrations in healthy mucosa but decreased concentrations in allergic inflammation (Benson et al. 2002).

Hence, it remains unknown whether the decrease in TGFβ1 transcription is related to the fact that DEHP attenuates the immune response or to the fact that TGF-β1 is already decreased in allergy mucosa.

Conclusions

In conclusion, our study provides the first results of short-term exposure to house dust containing low and high concentrations of DEHP on nasal mucosa of healthy and HDM-allergic human subjects. Healthy subjects were not affected by the dust exposures. Low doses of DEHP in house dust elicited a silent inflammation in nasal mucosa of HDM-allergic subjects on both the protein and mRNA level. High concentrations of DEHP in house dust attenuated this inflammation. Our results suggest a stimulating effect at low doses of DEHP and an attenuating effect at high doses. However, exposing adults for 3 hr in a short-term exposure setting is very different from long-term exposure of children to house dust and phthalates in their homes; these two populations may exhibit true differences in immunologic reactions.

**REFERENCES**

Andrade AJ, Grande SW, Talness CE, Grote K, Golombiewski A, Sterner-Kock A, et al. 2006. A dose-response study following in utero and lactational exposure to di-(2-ethyl-hexyl) phthalate (DEHP): effects on androgenic status, developmental landmarks and testicular histology in male offspring rats. Toxicology 225:64–74.

Benson M, Carlsson B, Carlsson L-M, Mostad P, Svensson PA, Cardell LD. 2002. DNA microarray analysis of transforming growth factor-β and related transcripts in nasal biopsies from patients with allergic rhinitis. Cytochrome 18:20–25.

Bornehag CG, Lundgren B, Wescaler C, Sigsgaard T, Hagerhed-Engman I, Sundell J. 2005. Phthalates in indoor dust and their association with building characteristics. Environ Health Perspect 113:1399–1404.

Bornehag CG, Sundell J, Wescaler C, Sigsgaard T, Lundgren B, Hasselgren M, et al. 2004. The association between asthma and allergic symptoms in children and phthalates in house dust: a nested case-control study. Environ Health Perspect 112:1393–1397.

Bouillard LA, Develeeschouwer MJ, Michel O. 2006. Characteristics of the home bacterial contamination and endotoxin related released. J Pharm Belg 61:63–66.

Butte W, Hoffmann W, Hostrup G, Schmidt A, Walker G. 2001. Endocrine disrupting chemicals in house dust: results of a representative monitoring. Gefahrstoff-Reinheitsvors. 61:19–23.

Colvin JS, Green RP, Schmahl J, Capel B, Ormiz DM. 2001. Male-to-female sex reversal in mice lacking fibroblast growth factor 9. Cell 104:875–886.

Dreborg S, Frew A. 1993. Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Position paper. Allergy 48:69–83.

Ear, Nose, and Throat Department. 2008. Full List of Array Data Available: http://www.unl-um.de/klinik/hmcklinik/ downloads/deutschle_2007.zip [accessed 1 February 2008].

Framme W, Lahrz T, Piloty M, Gehrt H, Oddo A, Ruden H. 2004. Occurrence of phthalates and musk fragrances in indoor air and dust from apartments and kindergartens in Berlin (Germany). Indoor Air 14:188–195.

Ghio AJ, Kim C, Devlin RB. 2000. Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers. Am J Respir Crit Care Med 162:981–988.

Gourlay T, Samartzis I, Stefanou D, Taylor K. 2003. Characteristics of the home bacterial contamination and endotoxin released release in allergens. Environ Health Perspect 112:1393–1397.

Hansen JS, Larsen ST, Poulsen LK, Nielsen GD. 2007. Adjuvant effect of inhaled mono-2-ethylhexyl phthalate in BALB/Cj mice. Toxicology 232:79–88.

Hokanson R, Henneman W, Hennissey M, Donnelly KC, McDonald T, Chowdhary P, et al. 2006. DEHP, bis(2-ethyl-hexyl) phthalate, alters gene expression in human cells: possible correlation with initiation of fetal developmental abnormalities. Hum Exp Toxicol 25:687–695.

Howdeshell KL, Furr J, Lambright CR, Rider CV, Wilson VS, Gray LE Jr. 2007. Cumulative effects of dibutyl phthalate and diethylhexyl phthalate on male rat reproductive tract development: altered fetal steroid hormones and genes. Toxicol Sci 95:190–202.
Hutter HP, Moshammer H, Wallner P, Damberger B, Tappler P, Kundl M. 2006. Health complaints and annoyance after moving into a new office building: a multidisciplinary approach including analysis of questionnaires, air and house dust samples. Int J Hyg Environ Health 209:65–68.

Jaakkola JJ, Die L, Naftsd P, Botten G, Samuelson SG, Magnus P. 1999. Interior surface materials in the home and the development of bronchial obstruction in young children in Oslo, Norway. Am J Public Health 89:188–192.

Jaakkola JJ, Verkasalo PK, Jaakkola N. 2000. Plastic wall materials in the home and respiratory health in young children. Am J Public Health 90:297–299.

Jepsen KF, Aalborg H, Larsen ST. 2004. Monophthalates promote IL-6 and IL-8 production in the human epithelial cell line AS49. Toxicol In Vitro 18:265–269.

Junker M, Koller T, Moen C. 2000. An assessment of indoor air contaminants in buildings with recreational activity. Sci Total Environ 246:139–152.

Keck T, Lehacker R, Klitz M, Lindemann J, Riechelmann H, Rettiging G. 2000. Detection of particles within the nasal airways during respiration. Eur Arch Otorhinolaryngol 257:493–497.

Kim IF, Han SY, Moon A. 2004. Phthalates inhibit tamoxifen-induced apoptosis in MCF-7 human breast cancer cells. J Toxicol Environ Health A 67:2025–2035.

Kolarik B, Naydenov K, Larsson M, Bornhag CG, Sundell J. 2008. The association between phthalates in dust and allergic diseases among Bulgarian children. Environ Health Perspect 116:98–103.

Larsen ST, Hansen JS, Hansen EW, Clausen PA, Nielsen GD. 2007. Airway inflammation and adjuvant effect after repeated airborne exposures to di-(2-ethylhexyl)phthalate and ovalbumin in BALB/c mice. Toxicology 235:119–129.

Larsen ST, Hansen JS, Thygesen P, Bergstrøm P, Poulsen OM, Nielsen GD. 2001a. Adjuvant and immune-suppressive effect of six monophthalates in a subcutaneous injection model with BALB/c mice. Toxicology 169:37–51.

Larsen ST, Lund RM, Nielsen GD, Thygesen P, Poulsen OM. 2001b. Di(2-ethylhexyl) phthalate possesses an adjuvant effect in a subcutaneous injection model with BALB/c mice. Toxicol Lett 125:11–18.

Larsen ST, Lund RM, Nielsen GD, Thygesen P, Poulsen OM. 2002. Adjuvant effect of di-n-butyl-, di-n-octyl-, di-iso-nonyl- and di-iso-decyl phthalate in a subcutaneous injection model using BALB/c mice. Pharmacol Toxicol 91:264–272.

Larsen ST, Nielsen GD. 2007. The adjuvant effect of di(2-ethylhexyl) phthalate is mediated through a PPARalpha-independent mechanism. Toxicol Lett 170:223–228.

Latinu G. 2005. Monitoring phthalate exposure in humans. Clin Chim Acta 361:20–29.

Lee MH, Park J, Chung SW, Kang BY, Kim SH, Kim TS. 2004. Enhancement of interleukin-4 production in activated CD4+ T cells by di(2-ethylhexyl)phthalate versus increased NF-AT binding activity. Int Arch Allergy Immunol 134:213–222.

Ma M, Kondo T, Ban S, Umemura T, Kurashita N, Takeda M, et al. 2006. Exposure of prepupal female rats to inhaled di(2-ethylhexyl)phthalate affects the onset of puberty and postpubertal reproductive functions. Toxicol Sci 93:164–171.

Mandard S, Muller M, Kersten S. 2004. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61:393–416.

Molhave L, Kjaergaard SK, Attermann J. 2004. Respiratory effects of experimental exposure to office dust. Indoor Air 14:376–384.

Pielra R, Sanchez-Cabo F, Hackl H, Thalinger GG, Trajanoski Z. 2004. ArrayNorm: comprehensive normalization and analysis of microarray data. Bioinformatics 20:1971–1973.

Plummer S, Sharpe RM, Hallmark N, Mahood IK, Elcombe C. 2007. Time-dependent and compartment-specific effects of in utero exposure to di(n-butyl) phthalate on gene/protein expression in the fetal rat testis as revealed by transcript profiling and laser capture microdissection. Toxicol Sci 97:520–532.

Pühner A, Simrock S, Thumann J, Weber S, Wirker T. 1997. Hintergrundbelastung des Hausstaubes von Privathaushalten mit mittel- und schwerflüchtigen organischen Schadstoffen [in German]. Z Umweltmed 6:337–345.

Praml G, Schiel R. 2000. Dust exposure in Munich public transport: a comprehensive 4-year survey in buses and trains. Int Arch Occup Environ Health 72:209–214.

Riechelmann H, Deutschle T, Friemel E, Gross HJ, Bachem M. 2003a. Biological markers in nasal secretions. Eur Respir J 21:600–605.

Riechelmann H, Deutschle T, Grabowa A, Heinutz B, Butte W, Reiter R. 2007. Differential response of Mono Mac 6, BEAS-2B, and Jurkat cells to indoor dust. Environ Health Perspect 115:1235–1239.

Riechelmann H, Epelke B, Gronper G. 2003b. Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 130:51–59.

Rowland TL, McHugh SM, Deighton J, Ewan PW, Dearman RJ, Kimber I. 2001. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B. Int Immunopharmacol 1:49–61.

Scheffler T. 2006. Human exposure to phthalates via consumer products. Int J Androl 29:134–138.

Schram-Bijkert D, Doekes G, Bovee M, Douwes J, Riedler J, Ublagger E, et al. 2006. Exposure to microbial components and allergens in population studies: a comparison of two house dust collection methods applied by participants and fieldworkers. Indoor Air 16:414–425.

Sharpe RM. 2006. Pathways of endocrine disruption during male sexual differentiation and masculinization. Best Pract Res Clin Endocrinol Metab 20:91–110.

Sharpe RM, Irvine DS. 2004. How strong is the evidence of a link between environmental chemicals and adverse effects on human reproductive health? BMJ 328:447–451.

Tsuchimine A, Stark H, Seuri M, Hirvonen MR, Linkinmaa M, Sieppi A, et al. 2006. Experimental PVC material challenge in subjects with occupational PVC exposure. Environ Health Perspect 114:1409–1413.

van Strien RT, Verhoef AP, Bruneel B, van Wijnen JH. 1994. Mite antigens in house dust: relationship with different housing characteristics in The Netherlands. Clin Exp Allergy 24:843–852.

Wain HM, Lush MJ, Ducluzeau F, Khodiyar VK, Povey S. 2004. Genew: the Human Gene Nomenclature Database, 2004 updates. Nucleic Acids Res 32:D255–D257.

Ward JM, Peters JM, Perolla CM, Gonzalez FJ. 1998. Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice. Toxicol Pathol 26:240–246.

Weichmann G, Mühlenberg J, Fischader G, Kulla C, Rehwaagen M, Herbartch O, et al. 2005. An experimental model for the determination of immunomodulating effects by volatile compounds. Toxicol In Vitro 19:685–693.

Wieslander G, Norback D, Nordstrom K, Walinder R, Venge P. 1999. Nasal and ocular symptoms, tear film stability and biomarkers in nasal lavage, in relation to building-dampness and building design in hospitals. Int Arch Occup Environ Health 72:451–461.

Zock JP, Heinrich J, Jarvis D, Verlato G, Norback D, Plana E, et al. 2006. Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II. J Allergy Clin Immunol 118:682–690.